— Know what they know.
Not Investment Advice

Financial News

Sentiment 40.6 5480 articles 2875 bullish 1201 bearish Full Index →
SANY und OCHA unterzeichnen Partnerschaftsvereinbarung bei d

SANY und OCHA unterzeichnen Partnerschaftsvereinbarung bei der HNPW 2026

PEKING, 19. März 2026 /PRNewswire/ -- Während der Humanitarian Networks and Partnerships Week (HNPW) 2026 unterzeichneten die SANY Foundation und das...
Woori IO, an OSR Company, Signs NDA with Sinopharm for China

Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials

BELLEVUE, Wash., March 19, 2026 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a healthcare-focused holding company advancing innovative medical...
📰

Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?

Here is how Biodesix, Inc. (BDSX) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
📰

Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?

Here is how Biodesix, Inc. (BDSX) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
📰

Aveanna (AVAH) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Aveanna (AVAH) give a sense of how its business performed in the quarter ended December 2025, it might be worth...
Hologic's Women's Health Index Flags Alarming Gaps in STI Sc

Hologic's Women's Health Index Flags Alarming Gaps in STI Screening

HOLX's Global Women's Health Index shows STI testing stagnates at 10%, leaving nearly 2 billion women at risk despite gains in other screenings.
Investors Heavily Search Johnson & Johnson (JNJ): Here is Wh

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CVS Health Corporation (CVS) Is a Trending Stock: Facts to K

CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It

CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD)

Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
📰

Notice to convene Evaxion’s Annual General Meeting

COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its...
Castlemead Joins TechAssure's Select Global Network of Speci

Castlemead Joins TechAssure's Select Global Network of Specialist Brokers

WASHINGTON, March 19, 2026 /PRNewswire/ -- TechAssure, the international network of insurance brokers specializing in complex and emerging risks, has...
📰

Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights

<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p...
📰

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

<ul xmlns="http://www.w3.org/1999/xhtml" type="disc"> <li xmlns="http://www.w3.org/1999/xhtml"><i...
📰

Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026

ASHBURN, Va., March 19, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage...
📰

Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights

Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing
📰

Sarepta pushes 2 Duchenne drugs toward traditional approval after mixed data - Stock Titan

Sarepta pushes 2 Duchenne drugs toward traditional approval after mixed data  Stock Titan
📰

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

CAMBRIDGE, Mass., March 19, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today...
« Prev 1 14 15 16 Next »

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms